TechConnect Innovation Program

Synthetic Immunotherapy Platform for Vaccine Development

Avalia Immunotherapies Limited, NA, New Zealand

TECHNOLOGY SUMMARY

Avalia Immunotherapies has developed a platform technology to deliver therapeutic cancer vaccines that activate the most powerful tumor-fighting cells in the body. The vaccines are discrete synthetic compounds that deliver both a cancer-specific peptide antigen and a powerful immune system activator simultaneously to dendritic cells.

Primary Application Area: Pharmaceuticals & Personal Care

Technology Development Status: Prototype

Technology Readiness Level: TRL 5

FIGURES OF MERIT

Value Proposition: Avalia’s technology has the potential to offer fully synthetic, therapeutic cancer vaccines that activate the most powerful tumor fighting cells in the body. The vaccines have a unique mechanism of action to immunotherapies in development and are also suitable for combination therapies, alongside traditional options, such as chemotherapy.

SHOWCASE SUMMARY

Organization Type: Early-stage Startup (Seed)

Global Innovation Awardee

Showcase Booth #: 401

Website: www.avaliaimmunotherapies.com

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date:

Primary Sources of Funding: Venture Capital, University

Looking for: Both Funding and Development Partners